BioInvent Announces Approval to Start Phase II Trial for Its Novel Cardiovascular Drug BI-204

LUND, Sweden--(BUSINESS WIRE)--BioInvent International AB (OMXS: BINV) today announces IND clearance from the U.S. Food & Drug Administration (FDA) to initiate a Phase II study for BI-204. BI-204 is a human monoclonal antibody that specifically targets oxidized forms of a low-density lipoprotein (LDL) which has been linked to increased inflammatory processes leading to plaque formation in the blood vessel walls. BI-204 is being co-developed with Genentech for secondary prevention of cardiovascular events in patients with acute coronary syndrome (ACS).
MORE ON THIS TOPIC